Escitalopram‑Associated Hyperprolactinemia: Evidence‑Based Guidelines

Incidence and Severity Compared with Antipsychotics

Hyperprolactinemia occurs in 40–90 % of patients receiving typical antipsychotics and 50–100 % of those on risperidone, far exceeding the rates seen with escitalopram or other SSRIs【1】【2】.
Antipsychotic‑induced prolactin elevations are usually 25–100 ng/mL, but agents such as metoclopramide, risperidone, and phenothiazines can raise levels above 200 ng/mL【1】【3】.

Women may develop galactorrhea, amenorrhea, or oligomenorrhea when prolactin is elevated by escitalopram or other SSRIs【1】【3】.
Men may experience decreased libido and erectile dysfunction under the same conditions【1】【3】.
Prolonged hyperprolactinemia can lead to bone loss (osteopenia/osteoporosis)【1】【4】.

When hyperprolactinemia is suspected to be escitalopram‑related, discontinue the drug for ≈ 3 days or switch to an alternative, then repeat serum prolactin measurement【2】【5】【6】.
Serum prolactin typically normalizes within 3 days after drug cessation【1】【2】【3】.
If the medication cannot be stopped and the timing of prolactin rise does not match therapy initiation, obtain a pituitary MRI to rule out a pituitary or hypothalamic mass【2】【5】【6】.

Asymptomatic, medication‑induced hyperprolactinemia does not require specific treatment【1】【7】【8】.
For symptomatic patients, the first step is to discontinue escitalopram if clinically feasible【7】【8】【3】.
When discontinuation is not possible, replace escitalopram with another antidepressant that lacks prolactin‑raising potential【7】【8】【3】.
In cases of long‑standing hypogonadism or low bone mass secondary to hyperprolactinemia, consider estrogen or testosterone replacement therapy【1】【7】【5】.

Systematically exclude other etiologies of hyperprolactinemia, including other prolactin‑raising drugs (especially antipsychotics), renal insufficiency, hypothyroidism, and parasellar tumors【6】.
Antipsychotics remain the most common non‑tumoral cause of elevated prolactin, with incidence substantially higher than that of SSRIs【1】【3】【6】.
Macroprolactinemia—a benign form caused by high‑molecular‑weight prolactin—accounts for ≈ 40 % of hyperprolactinemic patients and should be screened for using polyethylene glycol precipitation【6】.